Kura Oncology (KURA) 424B5 Prospectus supplement for primary offering

Exhibit 107

Calculation of Filing Fee Tables

424(b)(5)

(Form Type)

Kura Oncology, Inc.

(Exact Name of Registrant as Specified in its Charter)

Table 1: Newly Registered Securities

	Security Type		Security Class Title	Fee Calculation or Carry Forward Rule		Amount Registered			Proposed Maximum Offering Price Per Unit			Maximum Aggregate Offering Price			Fee Rate		Amount of Registration Fee(1)
Fees to Be Paid		Equity	Common stock, par value $0.0001 per share		Other		10,000,000	(2)	$	11.50		$	115,000,000.00			0.00011020	$	12,673.00
Fees to Be Paid		Equity	Pre-funded warrants to purchase common stock		Other		3,034,782		$	11.50	(3)		—	(3)		0.00011020		—	(3)
		Total Offering Amounts										$	115,000,000.00				$	12,673.00
		Total Fee Offsets																—
		Net Fee Due															$	12,673.00

(1) Calculated in accordance with Rule 457(r) under the Securities Act of 1933, as amended (the “Securities Act”). Payment of the registration fee at the time of filing of the registrant’s Registration Statement on Form S-3 (File No. 333-251172) on December 7, 2020 was deferred pursuant to Rules 456(b) and 457(r) under the Securities Act and is paid herewith.

(2) Includes 1,304,347 shares of common stock that the underwriters have an option to purchase and 3,034,782 shares of common stock that are issuable upon the exercise of pre-funded warrants referenced below.

(3) Represents the sum of the pre-funded warrant sales price of $11.4999 per warrant and the exercise price of $0.0001 per share issuable pursuant to the pre-funded warrants. Pursuant to Securities and Exchange Commission staff interpretation, the entire fee is allocated to the common stock underlying the pre-funded warrants.